Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (41-50 of 334) with videos related to

Pageof 34
Sort By:
European Urology|September 12, 2015
Reply from Authors re: Vincent Khoo. Is There Another Bite of the Cherry? The Case for Radical Local Therapy for Oligometastatic Disease in Prostate Cancer. Eur Urol 2016;69:13-4: Oligometastatic Prostate Cancer: More Than Just Cherry-picking?Barbara Alicja Jereczek-Fossa, Piet Ost, Gert De Meerleer
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 21, 2002
Short term toxicity profile for 32 sinonasal cancer patients treated with IMRT. Can we avoid dry eye syndrome?Filip Claus, Tom Boterberg, Piet Ost, et al.
Non-Coding RNA Research|August 31, 2018
Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?Hetty Helsmoortel, Celine Everaert, Nicolaas Lumen, et al.
World Journal of Urology|November 1, 2017
AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?Igor Tsaur, Hendrik Borgmann, Christian I Surcel, et al.
Advances in Urology|December 23, 2011
Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancerValérie Fonteyne, Nicolaas Lumen, Geert Villeirs, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 8, 2022
Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors: A systematic review of the literatureWilleke Danckaert, Mathieu Spaas, Katrien Vandecasteele, et al.
World Journal of Urology|January 20, 2020
Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registriesAurélie De Bruycker, Phuoc T Tran, Ariel H Achtman, et al.
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
Effects of radiation on the metastatic processNora Sundahl, Fréderic Duprez, Piet Ost, et al.
Journal of Thoracic Imaging|March 19, 2008
F-18 fluorodeoxyglucose PET/CT scanning in the diagnostic work-up of a primary pericardial mesothelioma: a case reportPiet Ost, Sylvie Rottey, Peter Smeets, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2010
A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancerPiet Ost, Bart De Troyer, Valérie Fonteyne, et al.
Pageof 34

Showing results (41-50 of 334) with videos related to

Sort By:
Pageof 34
European Urology|September 12, 2015
Reply from Authors re: Vincent Khoo. Is There Another Bite of the Cherry? The Case for Radical Local Therapy for Oligometastatic Disease in Prostate Cancer. Eur Urol 2016;69:13-4: Oligometastatic Prostate Cancer: More Than Just Cherry-picking?Barbara Alicja Jereczek-Fossa, Piet Ost, Gert De Meerleer
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 21, 2002
Short term toxicity profile for 32 sinonasal cancer patients treated with IMRT. Can we avoid dry eye syndrome?Filip Claus, Tom Boterberg, Piet Ost, et al.
Non-Coding RNA Research|August 31, 2018
Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?Hetty Helsmoortel, Celine Everaert, Nicolaas Lumen, et al.
World Journal of Urology|November 1, 2017
AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?Igor Tsaur, Hendrik Borgmann, Christian I Surcel, et al.
Advances in Urology|December 23, 2011
Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancerValérie Fonteyne, Nicolaas Lumen, Geert Villeirs, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 8, 2022
Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors: A systematic review of the literatureWilleke Danckaert, Mathieu Spaas, Katrien Vandecasteele, et al.
World Journal of Urology|January 20, 2020
Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registriesAurélie De Bruycker, Phuoc T Tran, Ariel H Achtman, et al.
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
Effects of radiation on the metastatic processNora Sundahl, Fréderic Duprez, Piet Ost, et al.
Journal of Thoracic Imaging|March 19, 2008
F-18 fluorodeoxyglucose PET/CT scanning in the diagnostic work-up of a primary pericardial mesothelioma: a case reportPiet Ost, Sylvie Rottey, Peter Smeets, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2010
A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancerPiet Ost, Bart De Troyer, Valérie Fonteyne, et al.
Pageof 34